89BIO INC. - COMMON STOCK

89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASH

02 May 2024 15:05:00 By Nasdaq GlobeNewswire

89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors

17 Apr 2024 15:05:00 By Nasdaq GlobeNewswire

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 Apr 2024 15:05:00 By Nasdaq GlobeNewswire

89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis

27 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis

12 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

08 Mar 2024 15:05:00 By Nasdaq GlobeNewswire

89bio to Participate in the Leerink Partners Global Biopharma Conference

05 Mar 2024 15:05:00 By Nasdaq GlobeNewswire

89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

29 Feb 2024 15:05:00 By Nasdaq GlobeNewswire

89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

06 Feb 2024 15:05:00 By Nasdaq GlobeNewswire

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 Feb 2024 15:05:00 By Nasdaq GlobeNewswire

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

19 Dec 2023 15:05:00 By Nasdaq GlobeNewswire

89bio Announces Closing of its Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

12 Dec 2023 06:30:00 By Nasdaq GlobeNewswire

89bio, Inc. Announces Upsized Pricing of $150.0 Million Public Offering of Common Stock and Pre-Funded Warrants

07 Dec 2023 06:00:00 By Nasdaq GlobeNewswire

89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

06 Dec 2023 15:36:09 By Nasdaq GlobeNewswire

89bio Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH); Program Initiation Planned in the First Half of 2024

04 Dec 2023 06:00:00 By Nasdaq GlobeNewswire

89bio Announces New Positive Long-Term Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH)

27 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

89bio to Participate in the 6th Annual Evercore ISI HEALTHCONx Conference

21 Nov 2023 15:01:00 By Nasdaq GlobeNewswire

89bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

08 Nov 2023 15:01:00 By Nasdaq GlobeNewswire

89bio to Participate in the H.C. Wainwright 7ᵗʰ Annual NASH Investor Conference

17 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 Oct 2023 15:05:00 By Nasdaq GlobeNewswire